Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in ...
Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...
The MarketWatch News Department was not involved in the creation of this content.-- This marks the first live procedure at AAHS, as well as a first for Keenova. -- Treatment takes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback